Genu Recurvatum Market Report 2025

The genu recurvatum market size has grown strongly in recent years. It will grow from $7.62 billion in 2024 to $8.06 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to orthopedic conditions prevalence, the aging population, trauma and accidents, limited awareness, and early diagnosis.

The genu recurvatum market size is expected to see strong growth in the next few years. It will grow to $10.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising awareness and education, advancements in treatment options, sports injury prevention and management, and rehabilitation programs. Major trends in the forecast period include integration of digital health technologies, collaboration between orthopedic specialists and physical therapists, research on biomechanics and musculoskeletal health, focus on pediatric and adolescent cases, rehabilitation and strength training emphasis.

The growing incidence of orthopedic disorders is expected to drive the growth of the genu recurvatum market in the coming years. Orthopedic disorders encompass conditions that impact the musculoskeletal system, including bones, joints, muscles, tendons, ligaments, and cartilage. Genu recurvatum leads to knee pain and can result in knee osteoarthritis and other orthopedic issues. The rising number of orthopedic conditions will create a demand for treatment, thereby supporting the market's expansion. For example, in February 2022, the Office of Disease Prevention and Health Promotion, a U.S. government health agency, projected that by 2040, 78.4 million adults will have arthritis. Currently, over 52.5 million adult Americans, representing more than 22% of the population, are affected by arthritis. Thus, the increasing prevalence of orthopedic disorders is fueling the growth of the genu recurvatum market.

The rising aging population is anticipated to contribute to the growth of the genu recurvatum market moving forward. An aging population signifies a demographic shift characterized by a higher proportion of elderly individuals in society over time. Treatment for genu recurvatum among the elderly aims to address the underlying causes and enhance functional outcomes. For instance, in October 2022, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2030, one in every six individuals globally will be 60 years or older. During this period, the population aged 60 and above is expected to increase from 1 billion in 2020 to 1.4 billion. Furthermore, by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Therefore, the growing aging population is propelling the genu recurvatum market.

Technological advancements emerge as a significant trend in the genu recurvatum market, with major companies focusing on developing advanced products to maintain their market positions. In November 2022, Ortho Development Corporation, a US-based orthopedic device design and manufacturing company, introduced BKS Total PSI in collaboration with Materialize NV, a Belgium-based company specializing in 3D printing and additive manufacturing. BKS Total PSI, driven by Materialize, enhances total knee arthroplasty predictability and control through patient-specific virtual visualization, preoperative planning, and precise 3D-printed guidance.

Companies in the genu recurvatum market are channeling their efforts into the development of innovative solutions such as microprocessor prosthetic knees. A microprocessor prosthetic knee integrates microprocessor technology into artificial knee joints, improving the functionality and performance of prosthetic limbs. In September 2022, Össur, an Iceland-based non-invasive orthopedic equipment manufacturing company, launched the 'POWER KNEE,' touted as the world's first actively powered microprocessor prosthetic knee for individuals with knee amputation or limb differences. This groundbreaking bionic technology incorporates a motor-powered 'smart' prosthesis equipped with advanced algorithms. It can detect human movement patterns, learn from them, and dynamically adjust to the wearer's speed and cadence in real-time.

In April 2023, NuVasive, Inc., a US-based medical device company, completed a merger with Globus Medical, Inc. This strategic union brought together two esteemed technological entities within the Musculoskeletal sector. The merger aimed to enhance innovation, broaden global medical and commercial outreach, and bolster support for a larger patient base. Globus Medical Inc., a US-based firm, specializes in developing, manufacturing, and distributing musculoskeletal device solutions, including revision knee replacements.

Major companies operating in the genu recurvatum market include Medtronic plc, Johnson & Johnson MedTech, Stryker Corporation, DePuy Synthes Inc., Zimmer Inc., Smith & Nephew plc, Arthrex, NuVasive Inc., DJO Global Inc., Össur hf, AliMed Inc., Thuasne Ltd., Orthofix Inc, Prim SA, OrthoPro Inc., Performance Health, Trulife Group Limited, Breg Inc., Allard USA, Capstone Orthopedic Inc., BraceAbility, KevinRoot Medical.

North America was the largest region in the genu recurvatum market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genu recurvatum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genu recurvatum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Genu recurvatum is a medical condition characterized by the excessive extension of the knee joint, causing it to bend backward beyond its normal range. The primary treatments for this condition involve strengthening the quadriceps muscles, using a brace to prevent overextension, or considering a proximal tibial osteotomy procedure. This surgical procedure involves altering the slope of the tibia to reduce or eliminate the condition.

The various types of genu recurvatum include external rotatory deformity (ERD), internal rotatory deformity (IRD), and non-rotatory deformity (NRD). ERD specifically refers to a rotational deformity where the foot or leg bone is twisted outward. Diagnosis typically involves methods such as magnetic resonance imaging (MRI), x-rays, among others. Treatment options may include physical therapy, orthotic devices, bracing, or surgical intervention. The primary end users for addressing this condition include hospitals, clinics, and similar healthcare facilities.

The genu recurvatum market research report is one of a series of new reports that provides genu recurvatum market statistics, including genu recurvatum industry global market size, regional shares, competitors with a genu recurvatum market share, detailed genu recurvatum market segments, market trends and opportunities, and any further data you may need to thrive in the genu recurvatum industry. This genu recurvatum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genu recurvatum market includes of revenues earned by entities by providing services such as physiotherapy and strengthening of calf muscles. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.